Day One Biopharmaceuticals, Inc. Profile Avatar - Palmy Investing

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly …

Biotechnology
US, South San Francisco [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Day One Biopharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of DAWN's Analysis
CIK: 1845337 CUSIP: 23954D109 ISIN: US23954D1090 LEI: - UEI: -
Secondary Listings
DAWN has no secondary listings inside our databases.